Apollomics, Inc. (NASDAQ:APLM) Short Interest Down 49.5% in October

Posted by Xavier Holt on Nov 15th, 2024

Apollomics, Inc. (NASDAQ:APLM – Get Free Report) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 168,500 shares, a decline of 49.5% from the October 15th total of 333,700 shares. Based on an average daily volume of 3,690,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.3% of the shares of the company are sold short.

Apollomics Stock Performance

NASDAQ APLM traded down $0.01 during trading on Friday, reaching $0.10. The company’s stock had a trading volume of 1,180,711 shares, compared to its average volume of 1,507,501. Apollomics has a 12 month low of $0.08 and a 12 month high of $1.79. The firm has a 50 day moving average price of $0.13 and a 200 day moving average price of $0.19.

Institutional Investors Weigh In On Apollomics

An institutional investor recently raised its position in Apollomics stock. Exchange Traded Concepts LLC lifted its stake in shares of Apollomics, Inc. (NASDAQ:APLM – Free Report) by 247.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,259,117 shares of the company’s stock after purchasing an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned 1.41% of Apollomics worth $179,000 as of its most recent SEC filing. 19.13% of the stock is owned by hedge funds and other institutional investors.

About Apollomics

(Get Free Report)

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.